PURPOSE OF REVIEW:Since the late 1990 s, when a more uniform definition of idiopathic pulmonary fibrosis (IPF) was proposed, more than 3000 patients have been enrolled in clinical studies exploring novel therapies. Some of the most relevant trials have been published only recently.RECENT FINDINGS:This review describes and comments on the randomized clinical trials in IPF published within the past 18 months, with emphasis on the studies evaluating pirfenidone, which at present is the only drug approved for IPF (at least in Europe and Japan), and bosentan. This latter represents the largest single trial performed in IPF so far.SUMMARY:Despite multiple clinical trials, there is no strong, definitive evidence in favor of any agent to treat IPF. On the other hand, the placebo arms of these large trials have provided us with important critical information on the natural history of this disease. Clinical heterogeneity represents a critical issue to be taken into account in designing future clinical trials. The limited effectiveness of current treatment regimes has fuelled the search for a variety of new therapeutic approaches.

The big clinical trials in idiopathic pulmonary fibrosis / Luppi, F; Spagnolo, Paolo; Cerri, Stefania; Richeldi, Luca. - In: CURRENT OPINION IN PULMONARY MEDICINE. - ISSN 1070-5287. - STAMPA. - 18:(2012), pp. 428-432. [10.1097/MCP.0b013e3283567ff9]

The big clinical trials in idiopathic pulmonary fibrosis.

SPAGNOLO, Paolo;CERRI, Stefania;RICHELDI, Luca
2012-01-01

Abstract

PURPOSE OF REVIEW:Since the late 1990 s, when a more uniform definition of idiopathic pulmonary fibrosis (IPF) was proposed, more than 3000 patients have been enrolled in clinical studies exploring novel therapies. Some of the most relevant trials have been published only recently.RECENT FINDINGS:This review describes and comments on the randomized clinical trials in IPF published within the past 18 months, with emphasis on the studies evaluating pirfenidone, which at present is the only drug approved for IPF (at least in Europe and Japan), and bosentan. This latter represents the largest single trial performed in IPF so far.SUMMARY:Despite multiple clinical trials, there is no strong, definitive evidence in favor of any agent to treat IPF. On the other hand, the placebo arms of these large trials have provided us with important critical information on the natural history of this disease. Clinical heterogeneity represents a critical issue to be taken into account in designing future clinical trials. The limited effectiveness of current treatment regimes has fuelled the search for a variety of new therapeutic approaches.
18
428
432
The big clinical trials in idiopathic pulmonary fibrosis / Luppi, F; Spagnolo, Paolo; Cerri, Stefania; Richeldi, Luca. - In: CURRENT OPINION IN PULMONARY MEDICINE. - ISSN 1070-5287. - STAMPA. - 18:(2012), pp. 428-432. [10.1097/MCP.0b013e3283567ff9]
Luppi, F; Spagnolo, Paolo; Cerri, Stefania; Richeldi, Luca
File in questo prodotto:
File Dimensione Formato  
MCP697.pdf

non disponibili

Tipologia: Versione pubblicata dall'editore
Dimensione 137.77 kB
Formato Adobe PDF
137.77 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/743347
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 27
social impact